JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

Home・Aandelen Lijst・Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics Inc

Gesloten

SectorGezondheidszorg

20.01

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

19.94

Max

20.14

Belangrijke statistieken
By Trading Economics
Inkomsten	9.2M -16M
Verkoop	16M 82M
Winstmarge	-19.491
Werknemers	342
EBITDA	6.7M -12M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+20.19% upside

Dividenden
By Dow Jones
Volgende Winsten	28 okt 2025

Marktinformatie
By TradingEconomics
Marktkapitalisatie	773M 2.5B
Vorige openingsprijs	20.01
Vorige sluitingsprijs	20.01

Nieuwssentiment

By Acuity

50%

147 / 371 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Strong Bearish Evidence

12.42 / 14.93 Steun & Weerstand

Arcutis Biotherapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

24 okt 2025, 18:41 UTC

Winsten

Procter & Gamble to Focus on Innovation, Not Discounts, to Attract Wary Shoppers - 2nd Update

24 okt 2025, 18:31 UTC

Winsten

Correction to Procter & Gamble to Focus on Innovation

24 okt 2025, 16:25 UTC

Belangrijke Marktbewegers

Obook Shares Rise, Company Secures New Money Transmitter Licenses

24 okt 2025, 21:24 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

24 okt 2025, 21:24 UTC

Marktinformatie

Moody's Sees France With Increased Risk of Political Dysfunction -- Market Talk

24 okt 2025, 21:07 UTC

Winsten

The Score: Netflix, Amazon.com, Six Flags and More Stocks That Defined the Week -- WSJ

24 okt 2025, 20:58 UTC

Winsten

S&P 500 Climbs to New Record on Strong Earnings -- WSJ

24 okt 2025, 20:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

24 okt 2025, 20:40 UTC

Winsten

Intel Expects Chip Shortages on Better PC Demand. Here's Why AMD Is Winning Too. -- Barrons.com

24 okt 2025, 20:24 UTC

Winsten

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24 okt 2025, 20:23 UTC

Winsten

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24 okt 2025, 20:13 UTC

Winsten

These Stocks Moved the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 okt 2025, 20:07 UTC

Marktinformatie

Different-Cell Imputation Rose Proportionally in September CPI -- Market Talk

24 okt 2025, 19:40 UTC

Marktinformatie

Treasury Yields Mixed, Dollar Stronger Ahead of Fed Week -- Market Talk

24 okt 2025, 19:35 UTC

Marktinformatie

Oil Rally on U.S. Russia Sanctions Loses Steam -- Market Talk

24 okt 2025, 19:33 UTC

Winsten

IBM and Google Are Also Making Moves in Quantum. Don't Count Out the Bigger Players. -- Barrons.com

24 okt 2025, 19:29 UTC

Marktinformatie

U.S. Natural Gas Ends Week Higher on Weather Outlook -- Market Talk

24 okt 2025, 18:52 UTC

Winsten

Correction to GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24 okt 2025, 18:41 UTC

Winsten

GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24 okt 2025, 18:03 UTC

Winsten

Beyond Meat Stock Is on a Wild Ride. Why a Meme Rally Looks Undercooked. -- Barrons.com

24 okt 2025, 18:02 UTC

Winsten

Progressive Stock Got Hit After Earnings. It's Time to Buy One of America's Great Companies. -- Barrons.com

24 okt 2025, 18:00 UTC

Marktinformatie

U.S. Oil Rig Count Rises By Two to 420 -- Market Talk

24 okt 2025, 16:57 UTC

Winsten

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

24 okt 2025, 16:54 UTC

Marktinformatie

End to Canada-U.S. Trade Talks Not Seen Shifting Nearterm Outlook -- Market Talk

24 okt 2025, 16:44 UTC

Marktinformatie

Winsten

Amazon Retail Looks Strong as Consumer Sentiment Improves -- Market Talk

24 okt 2025, 16:39 UTC

Marktinformatie

Winsten

Amazon Sentiment Around AWS Seen as Improving in 3Q -- Market Talk

24 okt 2025, 16:33 UTC

Winsten

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 okt 2025, 16:23 UTC

Winsten

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 okt 2025, 16:20 UTC

Marktinformatie

Financial Services Roundup: Market Talk

24 okt 2025, 16:07 UTC

Winsten

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

Peer Vergelijking

Prijswijziging

Arcutis Biotherapeutics Inc Prognose

Koersdoel

By TipRanks

20.19% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 24.17 USD 20.19%

Hoogste 29 USD

Laagste 21 USD

Gebaseerd op 6 Wall Street-analisten die 12-maands prijsdoelen bieden voor Arcutis Biotherapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

6 ratings

Buy

Hold

Sell

Gebaseerd op 6 analisten die aandelenratings hebben gegeven aan Arcutis Biotherapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

12.42 / 14.93Steun & Weerstand

Recent bearish events outweigh bullish events.

There is one bullish event.

Sentiment

By Acuity

147 / 371 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.